reshma-bio-image

Vertex promote chief medical officer to CEO as Jeffrey Leiden steps down

July 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Dr Reshma Kewalramani has been made the new Vertex CEO. Vertex’s Chief Medical Officer Dr Kewalramani will succeed current CEO …

christi_shaw

Christi Shaw taken on by Gilead as Kite Pharma’s new CEO

July 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO. Shaw comes to Gilead’s cancer immunotherapy firm, …

opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019
Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

30805878966_19824f12fd_z

MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

July 25, 2019
Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …

opioid_naloxone_device

Researchers design automatic opioid overdose antidote device

July 25, 2019
Research and Development naloxone, opioid crisis, opioids, pharma, purdue university

Researchers at Purdue University are developing a device that would automatically detect an overdose in opioid users and release a …

lilly_entrance_web

Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection

July 25, 2019
Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma

Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …

Elizabeth Warren calls on Albert Bourla to reveal detail of appointment of former FDA commissioner Scott Gottlieb to Pfizer’s board

July 25, 2019
Business Services, Medical Communications Albert Bourla, Elizabeth Warren, FDA, Pfizer, Scott Gottlieb, pharma

Elizabeth Warren has called on Pfizer to reveal the details of Scott Gottlieb’s appointment to the company’s Board of Directors.

jonathan_symonds

GSK hire Jonathan Symonds as new Chairman

July 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Business chief Jonathan Symonds has joined British multinational GlaxoSmithKline as the company’s new non-executive chairman. The hire ends GSK’s six …

mike-thompson-blue-bg

ABPI Chief Executive Mike Thompson to retire by the end of 2019

July 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Chief Executive Mike Thompson is to retire from his role at the Association of the British Pharmaceutical Industry (ABPI) by …

humira_abbott__4

Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

July 24, 2019
Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …

Senate puts forward bipartisan bill to lower price of drugs

July 24, 2019
Research and Development PBMs, Senate, USA, access, bipartisan, pharma, pricing

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …

fda2outsideweb

FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan

July 24, 2019
Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma

Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …

Researchers use machine learning to re-identify ‘anonymous data’

July 24, 2019
Research and Development Big Data, anonymous data, data, patient data, privacy, research

Anonymised data can be traced back to individuals, according to research published in the journal Nature Communications. Anonymised data can …

1920px-hiv-budding-color

MSD trials long lasting PrEP implant for preventing HIV

July 23, 2019
Research and Development AIDS, HIV, MSD, PrEP, pharma

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

dr_alvin_shih

Disarm Therapeutics hires Dr Alvin Shih as new President and CEO

July 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO. The Cambridge, Mass.-based firm has …

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

bug_plants_insect_leaf_nature_macrophotography_naturephotography_macro-1046343

Drug resistant malaria spreads in South East Asia

July 23, 2019
Manufacturing and Production South East Asia, global health, infectious diseases, malaria, parasites

Drug resistant malaria parasites are spreading rapidly in South East Asia, according to researchers from Thailand and the United Kingdom. …

FDA approves nine generic versions of Pfizer’s Lyrica

July 23, 2019
Manufacturing and Production, Sales and Marketing FDA, Lyrica, Pfizer, pharma

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …

schizophrenia

Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

gilead-sciences

Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes

July 23, 2019
Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …

The Gateway to Local Adoption Series

Latest content